Cytokinetics
CYTK
50.78
-0.68
-1.32%
Cytokinetics
US · CYTK
#1564 by market cap
Listed 1970
50.78
-0.68
-1.32%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
D+
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: UBS moved from Hold to Buy on 2026-06-29.
Analyst consensus 16 analysts
Buy
Avg price target 107.29 +111.3%
Price target rangecurrent 50.78
Low78.00
Avg107.29
High140.00
Buy 94%
Hold 6%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-09 | H.C. Wainwright | -- | Buy | 140.00 |
| 2026-11-06 | Truist Financial | -- | Buy | 112.00 |
| 2026-11-06 | Citi | -- | Buy | 105.00 |
| 2026-11-05 | Wells Fargo | -- | Buy | 105.00 |
| 2026-11-05 | Piper Sandler | -- | Buy | 107.00 |
| 2026-11-05 | Morgan Stanley | -- | Buy | 103.00 |
| 2026-11-05 | Evercore | -- | Buy | 100.00 |
| 2026-11-05 | Stifel | -- | Buy | 108.00 |
| 2026-11-05 | Citi | -- | Buy | 105.00 |
| 2026-11-05 | H.C. Wainwright | -- | Buy | 140.00 |
| 2026-11-05 | Barclays | -- | Buy | 110.00 |
| 2026-11-04 | BofA Securities | -- | Hold | 78.00 |
| 2026-11-04 | RBC Capital | -- | Buy | 113.00 |
| 2026-11-03 | Morgan Stanley | -- | Buy | 103.00 |
| 2026-10-19 | BofA Securities | -- | Hold | 81.00 |
| 2026-10-19 | H.C. Wainwright | -- | Buy | 140.00 |
| 2026-10-15 | William Blair | -- | Buy | -- |
| 2026-10-15 | UBS | -- | Buy | 104.00 |
| 2026-10-14 | UBS | -- | Buy | 104.00 |
| 2026-10-14 | RBC Capital | -- | Buy | 113.00 |
| 2026-10-14 | J.P. Morgan | -- | Buy | -- |
| 2026-10-13 | H.C. Wainwright | -- | Buy | 140.00 |
| 2026-10-08 | RBC Capital | -- | Buy | 113.00 |
| 2026-10-05 | Needham | -- | Buy | 112.00 |
| 2026-10-05 | H.C. Wainwright | -- | Buy | 140.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-06-29 | UBS | Hold → Buy | 115.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-04 | After close | ±8.89% | -12.66% (beat) |
| 2026/Q2 | 2026-08-06 | After close | ±7.47% | -5.67% (in line) |
| 2026/Q1 | 2026-05-05 | After close | ±9.52% | -2.92% (in line) |
| 2025/Q4 | 2026-02-24 | After close | ±9.08% | -10.29% (beat) |
| 2025/Q3 | 2025-11-05 | After close | ±7.87% | +1.88% (in line) |
| 2025/Q2 | 2025-08-07 | After close | ±11.80% | -3.23% (in line) |
| 2025/Q1 | 2025-05-06 | After close | ±15.94% | -2.74% (in line) |
| 2024/Q4 | 2025-02-27 | After close | ±16.40% | -3.06% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±10.73% | +0.61% (in line) |
| 2024/Q2 | 2024-08-08 | After close | ±14.46% | +3.31% (in line) |
| 2024/Q1 | 2024-05-08 | After close | ±6.51% | -1.92% (in line) |
| 2023/Q4 | 2024-02-27 | After close | ±7.96% | -9.75% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.
Cytokinetics discussion 0 comments